A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Inclusion criteria

• Patients with Parkinson's disease diagnosed by the British Parkinson's Disease Brain Bank Diagnostic Criteria can come to the hospital accompanied by family members
• drooling score using the Parkinson's Comprehensive Rating Scale (UPDRS) Part II (Item 6) ≥3;
• MMSE ≥ 10 points (recording the patient's education level)
• Adults over the age of 18
• The applicant or his/her caregiver must be able to complete the record of the salivation score
• Patients or family members voluntarily participate and sign an informed consent form.

Exclusion criteria

• Patients with non-primary Parkinson's disease
• Known allergy to dihydroergotamine mesylate
• Drug-induced hypersalivation, such as olanzapine, antipsychotics, clonazepam and other antiepileptic drugs, as well as direct and indirect cholinergic agonists for the treatment of Alzheimer's disease and myasthenia gravis
• BoNT treatment for saliva within the previous 3 months
• Patients with symptomatic bradycardia, severe orthostatic hypotension, symptomatic coronary insufficiency, severe organic cardiac damage, severe liver and kidney insufficiency: including ALT≥2.5ULN (upper limit of normal value of the executive laboratory); AST≥2.5ULN (upper limit of normal for the execution laboratory); Creatinine ≥ 1.5 ULN (upper limit of normal at the execution laboratory), active psychosis, pregnancy/pregnant woman